PROTECTION OF CHIMERIC SUBCELLULAR VACCINES AGAINST BRUCELLA OVIS IN RAMS

SILVIA M. ESTEIN; MARIA A. FIORENTINO; FERNANDO A. PAOLICCHI; MARIA CLAUSSE; JORGE MANAZZA; JULIANA CASSATARO; GUILLERMO H. GIAMBARTOLOMEI; LORENA M. CORIA; VANESA ZYLBERMAN; CARLOS A. FOSSATI; FERNANDO A. GOLDBAUM

Tandil. Buenos Aires

Congreso; Cuadragesima Reunion Anual de La Sociedad Argentina de Farmacología Experimental (SAFE); 2008

Sociedad Argentina de Farmacología Experimental (SAFE

Chimera BLS-OMP31 as a recombinant protein (BLS-Omp31) or DNA vaccine (pCIbls-Omp31) have been identified as protective antigens against B. ovis in mice. Groups of 10 rams were vaccinated three times with: a) Chimera in oil based adjuvant (AFI), b) Chimera in saponin (QUIL A), c) DNA with electro-poration, d) DNA without electroporation and e) Prime-boost (PB) (3 times with electroporated DNA, and a fourth with protein). Control group was immunized with hot saline extract (HS) of B. ovis. Rams were challenged with virulent B. ovis 7 months after last immunization and slaughtered 6 months thereafter, taking bacteriological samples from 12 organs. Chimera in AFI and PB strategy induced the highest IgG specific antibodies followed by chimera in QUIL A. Electroporation enhanced humoral immune response in DNA vaccinated rams. However PB stimulated the best levels of specific gamma IFN. The highest rates of protection were obtained with PB (75%) and chimera with AFI (63%). In the other groups the level of protection reminded between 10-20 %, including HS vaccine. Percentages of infection in unvaccinated rams and DNA without electroporation were 100 %. Chimera should be considered as potential vaccine in ovine brucellosis.